| Not Yet Recruiting | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted NCT06638125 | St. Joseph's Healthcare Hamilton | Phase 1 / Phase 2 |
| Not Yet Recruiting | Vapor Ablation for Localized Cancer Lesions NCT03514329 | Uptake Medical Technology, Inc. | N/A |
| Not Yet Recruiting | Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial NCT07382726 | M.D. Anderson Cancer Center | Phase 1 |
| Not Yet Recruiting | Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer NCT06552000 | University of Texas Southwestern Medical Center | N/A |
| Not Yet Recruiting | Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study NCT07412041 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Pathophysiological Mechanisms Involved in the Pronostic and Evolution of Non-Small Cell Lung Cancer (NSCLC) at NCT07470476 | University Hospital, Bordeaux | — |
| Not Yet Recruiting | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer NCT07285148 | Beijing Pearl Biotechnology Limited Liability Company | Phase 1 / Phase 2 |
| Not Yet Recruiting | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 NCT07361484 | BeyondSpring Pharmaceuticals Inc. | Phase 3 |
| Not Yet Recruiting | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for E NCT07279935 | AstraZeneca | Phase 4 |
| Not Yet Recruiting | Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer NCT06634056 | University Health Network, Toronto | Phase 2 |
| Not Yet Recruiting | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronida NCT07513376 | Merck Sharp & Dohme LLC | Phase 3 |
| Not Yet Recruiting | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progre NCT07001995 | Hunan Province Tumor Hospital | Phase 2 |
| Recruiting | DK222 Study at Hopkins NCT07140315 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Not Yet Recruiting | SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC NCT07489703 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC NCT07432984 | Se-Hoon Lee | Phase 2 |
| Suspended | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 NCT05642195 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigen NCT06694454 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer NCT07535463 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung NCT07500285 | Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization | Phase 2 |
| Recruiting | A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer NCT07535437 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy i NCT07507188 | Yonsei University | Phase 2 |
| Not Yet Recruiting | Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer NCT07477808 | Hunan Province Tumor Hospital | Phase 3 |
| Recruiting | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377 | EpiBiologics | Phase 1 |
| Not Yet Recruiting | A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer NCT07489716 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC NCT07392073 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Not Yet Recruiting | A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemot NCT07234877 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Not Yet Recruiting | Boosting Osimertinib Blood Brain Barrier Penetration NCT07485452 | Maastricht University Medical Center | Phase 2 |
| Not Yet Recruiting | Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial NCT07517640 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Not Yet Recruiting | Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanc NCT07489066 | Pfizer | Phase 2 |
| Not Yet Recruiting | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamou NCT07416474 | RemeGen Co., Ltd. | Phase 3 |
| Not Yet Recruiting | A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the NCT07412262 | Guangdong Association of Clinical Trials | Phase 2 |
| Not Yet Recruiting | A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patie NCT07464327 | Hansoh BioMedical R&D Company | Phase 3 |
| Recruiting | Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors NCT07487883 | Peking University People's Hospital | — |
| Active Not Recruiting | Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms NCT05987956 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Phase 2 / Phase 3 |
| Recruiting | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) NCT07431827 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Pulmonary Rehabilitation in Advanced Lung Cancer Survivors NCT07104630 | Case Comprehensive Cancer Center | Phase 2 |
| Not Yet Recruiting | Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients NCT07247786 | Fundación GECP | Phase 2 |
| Recruiting | Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients Wi NCT07336732 | Avistone Biotechnology Co., Ltd. | Phase 2 |
| Recruiting | ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-l NCT06951646 | Second Xiangya Hospital of Central South University | Phase 2 |
| Not Yet Recruiting | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ NCT07442565 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 |
| Recruiting | First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy NCT06439914 | Nerissa T. Viola | Phase 1 |
| Not Yet Recruiting | Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitiv NCT07416994 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 |
| Recruiting | CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC NCT07413757 | AstraZeneca | — |
| Recruiting | Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) NCT07460999 | Zealand University Hospital | N/A |
| Not Yet Recruiting | Concomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer NCT07489391 | University of Deusto | N/A |
| Not Yet Recruiting | The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 NCT07146230 | Montefiore Medical Center | Phase 2 |
| Not Yet Recruiting | Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis NCT07376512 | Centre Georges Francois Leclerc | — |
| Not Yet Recruiting | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer NCT07439094 | Chong Kun Dang Pharmaceutical | Phase 1 / Phase 2 |
| Not Yet Recruiting | SYS6090 Combination Therapy in Advanced Lung Cancer NCT07472647 | Shanghai JMT-Bio Inc. | Phase 1 / Phase 2 |
| Recruiting | Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC NCT07479277 | Fondazione del Piemonte per l'Oncologia | N/A |
| Not Yet Recruiting | 3D Virtual Resection for Predicting Lung Function in VATS NCT07436598 | National Taiwan University Hospital | — |
| Not Yet Recruiting | LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer NCT07444437 | Suzhou BlueHorse Therapeutics Co., Ltd. | Phase 2 |
| Recruiting | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808 | IDEAYA Biosciences | Phase 1 |
| Not Yet Recruiting | Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Adva NCT07377916 | The First Affiliated Hospital of Guangzhou Medical University | N/A |
| Recruiting | A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer NCT07428044 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Not Yet Recruiting | An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary NCT07461727 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Not Yet Recruiting | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy NCT07423117 | IntoCell, Inc | Phase 1 |
| Not Yet Recruiting | A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC NCT07418879 | Fudan University | N/A |
| Recruiting | Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC NCT07467863 | Beijing Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoad NCT07329322 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Lung Cancer Screening in Population Who Had Never Smoked NCT07383454 | Chung Shan Medical University | N/A |
| Not Yet Recruiting | Preoperative Structured Exercise Programme on Patients With Non-Small Cell Lung Cancer NCT07401056 | Hacettepe University | N/A |
| Recruiting | Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib NCT07374614 | Peking University Shenzhen Hospital | — |
| Recruiting | Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer NCT07250477 | University of California, Davis | Phase 2 |
| Not Yet Recruiting | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tu NCT07272642 | Radiopharm Theranostics, Ltd | Phase 1 |
| Recruiting | Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different NCT07227298 | Pfizer | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Adva NCT07271602 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC NCT06878274 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Not Yet Recruiting | First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Mal NCT07332858 | Gang Hou | Phase 1 / Phase 2 |
| Recruiting | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects NCT07269782 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | First in Human Study of SIM0610 in Solid Tumors NCT07348211 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung NCT07195695 | Boehringer Ingelheim | Phase 3 |
| Recruiting | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) NCT07320105 | Fujian Cancer Hospital | Phase 4 |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Can NCT07253142 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically NCT06931717 | ETOP IBCSG Partners Foundation | Phase 3 |
| Recruiting | Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer NCT07306624 | STCube, Inc. | Phase 2 |
| Not Yet Recruiting | Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell NCT07351565 | Chang Chen | Phase 1 |
| Recruiting | A Study in Non-Small Cell Lung Cancer NCT07174388 | N-Power Medicine | — |
| Recruiting | A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial L NCT07323732 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemother NCT07222566 | Pfizer | Phase 3 |
| Recruiting | An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC NCT07452003 | Peking Union Medical College Hospital | N/A |
| Recruiting | Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors NCT07161310 | Goethe University | N/A |
| Not Yet Recruiting | Exercise as a Tool to Improve Response to Immunotherapy in Non-small Cell Lung Cancer NCT07267000 | Medical University of Graz | N/A |
| Not Yet Recruiting | First in Human Study of QLS5316 in Solid Tumors NCT07358884 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients W NCT07310589 | National Taiwan University Hospital | N/A |
| Not Yet Recruiting | Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk NCT07347977 | First Affiliated Hospital of Ningbo University | N/A |
| Not Yet Recruiting | Electro-Acupuncture in Lung cancER : EALER Study NCT07337096 | Guangzhou University of Traditional Chinese Medicine | N/A |
| Recruiting | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562 | Cogent Biosciences, Inc. | Phase 1 |
| Recruiting | Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCL NCT07304739 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors NCT07358806 | Oscotec Inc. | Phase 1 |
| Recruiting | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HM NCT06956690 | Hummingbird Bioscience | Phase 1 / Phase 2 |
| Recruiting | PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC NCT06195527 | University Hospital, Angers | — |
| Recruiting | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor a NCT07185997 | ArriVent BioPharma, Inc. | Phase 3 |
| Recruiting | Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer NCT06686771 | Canadian Cancer Trials Group | Phase 3 |
| Recruiting | Promoting Immunotherapy Efficacy With Low-Dose Liver RT NCT07225036 | Jordan Kharofa | N/A |
| Recruiting | A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advan NCT07375316 | Guangdong Association of Clinical Trials | Phase 2 |
| Recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan C NCT07155187 | AbbVie | Phase 2 / Phase 3 |
| Recruiting | EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer NCT05467748 | VA Office of Research and Development | Phase 1 / Phase 2 |
| Recruiting | Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Ca NCT07485114 | Daniel Keizman | — |
| Recruiting | The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer NCT06477055 | Hunan Province Tumor Hospital | — |
| Not Yet Recruiting | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combi NCT06760676 | Anhui Provincial Hospital | Phase 1 |
| Not Yet Recruiting | Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT) NCT06711770 | University Hospital, Bordeaux | N/A |
| Recruiting | A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cel NCT07182682 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer NCT07249372 | NYU Langone Health | Phase 2 |
| Not Yet Recruiting | Minimal Residual Disease in Solid Malignancies NCT07268469 | European Institute of Oncology | N/A |
| Not Yet Recruiting | Is 3D Modeling From Non-contrast CT Accurate for Minimally Invasive Lung Segmentectomies ? NCT07234604 | University Hospital, Strasbourg, France | — |
| Active Not Recruiting | The HER Project: HRD in EGFR-mutated NSCLC NCT07303218 | IRCCS San Raffaele | — |
| Completed | Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Po NCT07526961 | Bristol-Myers Squibb | — |
| Recruiting | Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC NCT07239661 | Kong Fanming | N/A |
| Not Yet Recruiting | A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With NCT07256509 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 |
| Recruiting | FL-261 Imaging for Cancer Diagnosis and Staging NCT07510321 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Recruiting | A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib NCT07362940 | Henan Genuine Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer NCT07229729 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors NCT07300150 | PAQ Therapeutics, Inc. | Phase 1 |
| Enrolling By Invitation | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid T NCT07218003 | Rondo Therapeutics | Phase 1 |
| Recruiting | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid NCT07232420 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer NCT07133425 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung NCT07100080 | Bristol-Myers Squibb | Phase 2 / Phase 3 |
| Recruiting | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors NCT07216105 | Fate Therapeutics | Phase 1 |
| Recruiting | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424 | Diwakar Davar | Phase 2 |
| Enrolling By Invitation | Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Statu NCT07373951 | Ming Yang | — |
| Recruiting | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an NCT07192068 | UNICANCER | Phase 2 |
| Recruiting | A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, NCT07183189 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 |
| Recruiting | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors NCT07208773 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes NCT07215026 | AstraZeneca | — |
| Not Yet Recruiting | A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib NCT07164170 | Abbisko Therapeutics Co, Ltd | Phase 2 |
| Recruiting | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpress NCT06899126 | Daiichi Sankyo | Phase 3 |
| Recruiting | A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed NCT06793215 | Hoffmann-La Roche | Phase 3 |
| Recruiting | A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Adv NCT07027514 | Ankyra Therapeutics, Inc | Phase 1 |
| Recruiting | Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer NCT07218601 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer NCT07190248 | Merck Sharp & Dohme LLC | Phase 3 |
| Not Yet Recruiting | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy NCT07076914 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Recruiting | A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brai NCT06822543 | Latin American Cooperative Oncology Group | Phase 2 |
| Recruiting | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda NCT07160335 | Shanghai Henlius Biotech | Phase 1 |
| Not Yet Recruiting | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs NCT07154368 | Guangzhou JOYO Pharma Co., Ltd | Phase 3 |
| Recruiting | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentia NCT07111520 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer NCT07195084 | Anhui Provincial Cancer Hospital | N/A |
| Recruiting | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab a NCT06946797 | Bristol-Myers Squibb | Phase 2 |
| Recruiting | Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic Radiotherapy and Their Famil NCT07234799 | M.D. Anderson Cancer Center | N/A |
| Not Yet Recruiting | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors NCT07173244 | Tianjin First Central Hospital | — |
| Not Yet Recruiting | Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC NCT07177105 | Jianxing He | Phase 2 |
| Recruiting | A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non- NCT07174908 | InxMed (Shanghai) Co., Ltd. | Phase 3 |
| Recruiting | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496 | University of Arizona | Phase 1 / Phase 2 |
| Not Yet Recruiting | Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer NCT07177092 | Jianxing He | Phase 2 |
| Not Yet Recruiting | AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who NCT07158840 | Akeso | Phase 2 |
| Recruiting | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors NCT07169994 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424 | A2 Biotherapeutics Inc. | — |
| Recruiting | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors NCT07030257 | Tasca Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors NCT07020117 | Aktis Oncology, Inc. | Phase 1 |
| Not Yet Recruiting | Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC NCT07093762 | Fuzhou General Hospital | — |
| Recruiting | Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Can NCT07150663 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer NCT06868485 | Wayshine Biopharm, Inc. | Phase 2 |
| Completed | Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients NCT07143513 | Amgen | — |
| Recruiting | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) NCT07098338 | AstraZeneca | Phase 2 |
| Not Yet Recruiting | A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunot NCT07119190 | Peking University People's Hospital | — |
| Recruiting | A Study of YL202 in Patients With Advanced Solid Tumors NCT07202364 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Radiation-induced Toxicity of the Heart NCT06986291 | Technische Universität Dresden | N/A |
| Not Yet Recruiting | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer NCT07110363 | Biotroy Therapeutics | Phase 1 |
| Recruiting | Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR NCT07079475 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid NCT07056556 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection NCT07096882 | Cytocraft Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204 | Astellas Pharma Inc | Phase 1 |
| Recruiting | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizuma NCT06758401 | Pfizer | Phase 3 |
| Recruiting | Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advance NCT07086456 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer NCT06933329 | BicycleTx Limited | Phase 2 |
| Recruiting | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC NCT06765109 | Nuvalent Inc. | Phase 3 |
| Recruiting | DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHA NCT07070440 | Dizal Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518 | GV20 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Cancer of the Lung And SeneScencE - Prospective Cohort 1 NCT06923618 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC NCT07086300 | Kong Fanming | N/A |
| Recruiting | Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Sma NCT07153445 | Fundación GECP | Phase 2 |
| Recruiting | Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389 | Akeso | Phase 3 |
| Recruiting | A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive NCT06930794 | Beijing Pearl Biotechnology Limited Liability Company | Phase 3 |
| Completed | Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimerti NCT07213076 | AstraZeneca | — |
| Recruiting | Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung C NCT06877299 | Sichuan University | Phase 2 |
| Active Not Recruiting | 18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC NCT07449858 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Not Yet Recruiting | Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP A NCT07051928 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary NCT07073365 | Pusan National University Hospital | Phase 2 |
| Active Not Recruiting | Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer NCT07359040 | Peking University People's Hospital | — |
| Not Yet Recruiting | Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell NCT06974097 | University Hospital, Montpellier | — |
| Not Yet Recruiting | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therap NCT07031154 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Not Yet Recruiting | Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer NCT07035444 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | N/A |
| Recruiting | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combin NCT06962865 | RemeGen Co., Ltd. | Phase 2 |
| Recruiting | A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC NCT06951464 | Sichuan University | Phase 2 |
| Recruiting | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221 | Verastem, Inc. | Phase 1 / Phase 2 |
| Recruiting | JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC NCT06969027 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Recruiting | A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC NCT07193641 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC NCT06745882 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Ca NCT06902272 | University of Miami | Phase 2 |
| Recruiting | Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Im NCT07014202 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) NCT06907615 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Sm NCT07028489 | N-Power Medicine | — |
| Recruiting | Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell NCT07008742 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases NCT07008287 | Innovent Biologics (Suzhou) Co. Ltd. | — |
| Recruiting | FAP-targeted PET/NIR in Lung Malignant Tumors NCT07498933 | Peking University People's Hospital | — |
| Active Not Recruiting | Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Ce NCT07076693 | Shanghai Chest Hospital | Phase 2 / Phase 3 |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Withdrawn | Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases NCT06676917 | MedSIR | Phase 2 |
| Recruiting | Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC NCT06896422 | The First Affiliated Hospital of Zhengzhou University | Phase 1 |
| Not Yet Recruiting | Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy NCT06979661 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Recruiting | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC NCT06364917 | University of Alabama at Birmingham | Phase 2 |
| Not Yet Recruiting | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors NCT06963502 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Hybrid Prehabilitation Before Thoracic Surgery NCT06866717 | ADIR Association | N/A |
| Recruiting | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer NCT06903377 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | The Lung Health Check Pilot NCT07099027 | Royal College of Surgeons, Ireland | N/A |
| Withdrawn | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Vari NCT04889495 | Pfizer | — |
| Not Yet Recruiting | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated NCT06971406 | Qiming Wang | Phase 2 |
| Not Yet Recruiting | Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Adva NCT06970782 | Avistone Biotechnology Co., Ltd. | Phase 3 |
| Recruiting | Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of NCT06919874 | M.D. Anderson Cancer Center | N/A |
| Recruiting | A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR NCT06905197 | Dizal Pharmaceuticals | Phase 1 |
| Recruiting | A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced NCT07034391 | China Medical University, China | Phase 2 |
| Recruiting | Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 NCT06579196 | University of Nebraska | Phase 1 / Phase 2 |
| Recruiting | Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastat NCT06929936 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer NCT06972576 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Active Not Recruiting | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers NCT06870487 | Pfizer | Phase 1 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | Phase 2 Study of Fingolimod in Lung Cancers NCT06424067 | Medical University of South Carolina | Phase 2 |
| Not Yet Recruiting | Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutatio NCT06955325 | The First Affiliated Hospital of Guangzhou Medical University | Phase 3 |
| Not Yet Recruiting | NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC NCT06966583 | Sichuan University | Phase 1 |
| Not Yet Recruiting | Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cance NCT06828757 | Hunan Province Tumor Hospital | Phase 3 |
| Not Yet Recruiting | Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC NCT06934590 | GeneCraft Inc. | Phase 1 |
| Recruiting | A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer NCT06623136 | Elpiscience (Suzhou) Biopharma, Ltd. | Phase 2 |
| Recruiting | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies NCT07064018 | University of California, Irvine | Phase 1 / Phase 2 |
| Not Yet Recruiting | SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC NCT06925048 | Chunxia Su | Phase 2 |
| Recruiting | A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable N NCT06800339 | University of Maryland, Baltimore | Phase 1 |
| Recruiting | SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC NCT07131319 | Second Affiliated Hospital of Nanchang University | Phase 2 / Phase 3 |
| Active Not Recruiting | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617 | SystImmune Inc. | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-b NCT06829459 | Shanghai JMT-Bio Inc. | Phase 3 |
| Not Yet Recruiting | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined wit NCT06851169 | Tang-Du Hospital | Phase 2 |
| Not Yet Recruiting | Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer NCT06622174 | Houda Bahig | Phase 1 |
| Recruiting | BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Not Yet Recruiting | Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. NCT06885840 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced N NCT06731907 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative NCT06567704 | Wake Forest University Health Sciences | — |
| Recruiting | Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer NCT06930807 | Peking University People's Hospital | N/A |
| Recruiting | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With NCT06810544 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Fissios© and Postoperative Complications (FPoC Trial) NCT06732193 | Carlos Alfredo Fraile Olivero, MD, PhD. | N/A |
| Suspended | TOP 2301: Neoadjuvant Chemo for NSCLC NCT06385262 | Duke University | Phase 2 |
| Active Not Recruiting | A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC NCT06883630 | RemeGen Co., Ltd. | Phase 1 |
| Enrolling By Invitation | Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Tr NCT06883136 | Qianfoshan Hospital | — |
| Not Yet Recruiting | Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non- NCT06848426 | Jiangxi Provincial People's Hopital | N/A |
| Recruiting | Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small NCT06841055 | BioNTech SE | Phase 2 |
| Recruiting | A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer NCT06863233 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC NCT06846762 | Baohui Han | — |
| Not Yet Recruiting | Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutan NCT06890182 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy NCT06861543 | Peking Union Medical College Hospital | Phase 1 |
| Recruiting | Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCL NCT06849167 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 NCT06767514 | Summit Therapeutics | Phase 3 |
| Recruiting | Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer NCT07084610 | Hospital das Clínicas de Ribeirão Preto | Phase 2 |
| Recruiting | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer NCT06840704 | Hunan Cancer Hospital | Phase 3 |
| Recruiting | A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metas NCT06848699 | Shanghai Henlius Biotech | Phase 1 / Phase 2 |
| Recruiting | A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients Wit NCT06838273 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERU NCT06809764 | Daiichi Sankyo | — |
| Recruiting | A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC NCT06926413 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer NCT06731413 | Virginia Commonwealth University | Phase 2 |
| Recruiting | Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations NCT07117890 | Fudan University | Phase 2 |
| Not Yet Recruiting | Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer NCT06743581 | Centre hospitalier de l'Université de Montréal (CHUM) | N/A |
| Not Yet Recruiting | Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure NCT06786208 | Henan Cancer Hospital | — |
| Not Yet Recruiting | Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study NCT06743555 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 |
| Not Yet Recruiting | PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immu NCT06738680 | University Hospital, Brest | — |
| Recruiting | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors NCT06789172 | Epkin | Phase 1 |
| Recruiting | TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients NCT06455917 | University Hospital, Basel, Switzerland | Phase 2 |
| Recruiting | Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer NCT06889467 | Barzilai Medical Center | — |
| Recruiting | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Thr NCT06568939 | AbbVie | Phase 2 |
| Recruiting | Study on the Mechanism of Acquired Resistance of Entrectinib NCT07199959 | Fudan University | — |
| Recruiting | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL NCT06630611 | Vall d'Hebron Institute of Oncology | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer NCT06779539 | West China Hospital | Phase 2 |
| Recruiting | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients Wi NCT06284317 | ETOP IBCSG Partners Foundation | Phase 3 |
| Recruiting | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845 | Jazz Pharmaceuticals | Phase 2 |
| Recruiting | The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time NCT06540196 | St. Joseph's Healthcare Hamilton | N/A |
| Active Not Recruiting | A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemo NCT07005336 | TJ Biopharma Co., Ltd. | Phase 2 |
| Recruiting | Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC NCT05669846 | Diwakar Davar | Phase 2 |
| Recruiting | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Ag NCT06712316 | BioNTech SE | Phase 2 / Phase 3 |
| Recruiting | A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963 | NextCure, Inc. | Phase 1 |
| Not Yet Recruiting | SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC) NCT06646770 | Istanbul University - Cerrahpasa | N/A |
| Completed | ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery NCT07201077 | Jianxing He | N/A |
| Not Yet Recruiting | The Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive NCT06768853 | Zhongnan Hospital | N/A |
| Recruiting | Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small C NCT07057102 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Active Not Recruiting | Brain Oligometastasis in NSCLC NCT07389642 | University Hospital, Bordeaux | — |
| Recruiting | Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stag NCT07034326 | Kong Fanming | Phase 2 / Phase 3 |
| Withdrawn | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors NCT06681870 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Recruiting | 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC NCT06756217 | Ruijin Hospital | — |
| Recruiting | Early Palliative Care in Patients With Advanced Lung Cancer Using an e-Health Ecosystem NCT07039994 | Jesús González | N/A |
| Recruiting | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metasta NCT06643000 | Henan Cancer Hospital | N/A |
| Not Yet Recruiting | Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metas NCT06752408 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors NCT06621563 | Hansoh BioMedical R&D Company | Phase 1 |
| Withdrawn | Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cance NCT06522360 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer NCT07130916 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lu NCT06685718 | BeOne Medicines | Phase 1 |
| Not Yet Recruiting | Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC NCT06694129 | National Cancer Center, China | — |
| Not Yet Recruiting | Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC NCT06554613 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Not Yet Recruiting | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TK NCT06634667 | Hunan Province Tumor Hospital | Phase 2 |
| Active Not Recruiting | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC NCT06671379 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 |
| Recruiting | A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor NCT06670196 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastati NCT06564324 | Nuvation Bio Inc. | Phase 3 |
| Recruiting | Multicenter Analysis of Different Approaches in Segmentectomies in Early-stage Lung Cancer NCT06737107 | Scientific Institute San Raffaele | — |
| Recruiting | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers NCT06422403 | National University Hospital, Singapore | Phase 2 |
| Recruiting | Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions NCT07401615 | Istituto Clinico Humanitas | — |